In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more. Read the full coverage here:
Lobectomy alternatives show varying adverse event profiles in early-stage lung cancer
More frequent CT scans not linked to better outcomes after lung cancer surgery
Osimertinib-related pneumonitis incidence higher in real-world lung cancer population
FDA approves adjuvant Keytruda for non-small cell lung cancer
Tarlatamab active in recurrent small cell lung cancer
References:
Heiden BT, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djac208.
Paz-Ares L, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.02823.
Sato Y, et al. CHEST. 2022;doi:10.1016/j.chest.2022.05.035.
Wang Q, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202203-275OC.
